The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Treatment of Multidrug‐Resistant Acinetobacter baumannii Ventilator‐Associated Pneumonia (VAP) with Intravenous Colistin: A Comparison with Imipenem‐Susceptible VAP
Abstract
We prospectively evaluated the efficacy and toxicity of intravenously administered colistin in 35 episodes of ventilator-associated pneumonia (VAP) due to multidrug-resistant Acinetobacter baumannii. Microbiological diagnosis was performed with use of quantitative culture. In 21 patients, the episodes were caused by a strain susceptible exclusively to colistin (the CO group) and were all treated with this antimicrobial intravenously. In 14 patients, the episodes were caused by strains that remained susceptible to imipenem and were treated with imipenem-cilastatin (the IM group). Acute Physiology and Chronic Health Evaluation II scores at the time of admission and Sequential Organ Failure Assessment scores at time of diagnosis were similar in both groups. VAP was considered clinically cured in 57% of cases in both groups. In-hospital mortality rates were 61.9% in the CO group and 64.2% in the IM group, and the VAP-related mortality rates were 38% and 35.7%, respectively. Four patients in the CO group and 6 in the IM group developed renal failure. Neurophysiological evaluation was performed during 12 episodes in the CO group, but it revealed no signs of neuromuscular blockade. Intravenous colistin appears to be a safe and effective alternative to imipenem for the management of VAP due to carbapenem-resistant strains of A. baumannii.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Nosocomial infections in medical intensive care units in the United States
Richards, M. J., Edwards, J. R., Culver, D. H., & Gaynes, R. P. (1999) · Critical Care Medicine · doi:10.1097/00003246-199905000-00020 · Cited by 1,565
Fagon, J.-Y., Chastre, J., Hance, A. J., Montravers, P., Novara, A., & Gibert, C. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90060-3 · Cited by 1,180
Alvarez-Lerma, F., & ICU-Acquired Pneumonia Study Group (1996) · Intensive Care Medicine · doi:10.1007/bf01712153 · Cited by 652
Levin, A. S., Barone, A. A., Penço, J., Santos, M. V., Marinho, I. S., Arruda, E. A. G., Manrique, E. I., & Costa, S. F. (1999) · Clinical Infectious Diseases · doi:10.1086/514732 · Cited by 612
Cited by
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii
Dijkshoorn, L., Nemec, A., & Seifert, H. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1789 · Cited by 1,828
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Global Challenge of Multidrug-Resistant Acinetobacter baumannii
Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., & Bonomo, R. A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01464-06 · Cited by 1,139
The Epidemiology and Control of Acinetobacter baumannii in Health Care Facilities
Fournier, P. E., Richet, H., & Weinstein, R. A. (2006) · Clinical Infectious Diseases · doi:10.1086/500202 · Cited by 995
Maragakis, L. L., & Perl, T. M. (2008) · Clinical Infectious Diseases · doi:10.1086/529198 · Cited by 969
The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections
Driscoll, J. A., Brody, S. L., & Kollef, M. H. (2007) · Drugs · doi:10.2165/00003495-200767030-00003 · Cited by 884
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies
Falagas, M. E., & Kasiakou, S. K. (2006) · Critical Care · doi:10.1186/cc3995 · Cited by 828
Munoz-Price, L. S., & Weinstein, R. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra070741 · Cited by 772
Ayoub Moubareck, C., & Hammoudi Halat, D. (2020) · Antibiotics · doi:10.3390/antibiotics9030119 · Cited by 627
Colistin: an update on the antibiotic of the 21st century
Biswas, S., Brunel, J.-M., Dubus, J.-C., Reynaud-Gaubert, M., & Rolain, J.-M. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.78 · Cited by 581
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria
Li, J., Nation, R. L., Milne, R. W., Turnidge, J. D., & Coulthard, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.10.001 · Cited by 571
Landman, D., Georgescu, C., Martin, D. A., & Quale, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00006-08 · Cited by 565
Pamp, S. J., Gjermansen, M., Johansen, H. K., & Tolker‐Nielsen, T. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06152.x · Cited by 486
Hirsch, E. B., & Tam, V. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq108 · Cited by 477
World Health Organization Report: Current Crisis of Antibiotic Resistance
Talebi Bezmin Abadi, A., Rizvanov, A. A., Haertlé, T., & Blatt, N. L. (2019) · BioNanoScience · doi:10.1007/s12668-019-00658-4 · Cited by 465
Acinetobacter: an old friend, but a new enemy
Towner, K. J. (2009) · Journal of Hospital Infection · doi:10.1016/j.jhin.2009.03.032 · Cited by 458
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections
Karageorgopoulos, D. E., & Falagas, M. E. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70279-2 · Cited by 446
Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing
Lim, L. M., Ly, N., Anderson, D., Yang, J. C., Macander, L., Jarkowski, A., Forrest, A., Bulitta, J. B., & Tsuji, B. T. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.12.1279 · Cited by 444
Rescuing the Last-Line Polymyxins: Achievements and Challenges
Nang, S. C., Azad, M. A. K., Velkov, T., Zhou, Q. (., & Li, J. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000020 · Cited by 421
Falagas, M. E., Koletsi, P. K., & Bliziotis, I. A. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46747-0 · Cited by 399
Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?
Falagas, M. E., & Bliziotis, I. A. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.12.012 · Cited by 393
Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance
Gordon, N. C., & Wareham, D. W. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.024 · Cited by 378
Hawkey, P. M., Warren, R. E., Livermore, D. M., McNulty, C. A. M., Enoch, D. A., Otter, J. A., & Wilson, A. P. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky027 · Cited by 334
Antimicrobial resistance of Acinetobacter spp. in Europe
Van Looveren, M., & Goossens, H. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00942.x · Cited by 327
Acinetobacter baumannii: Evolution of Antimicrobial Resistance—Treatment Options
Murray, G., Peleg, A., & Doi, Y. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1398388 · Cited by 316
Micek, S. T., Ward, S., Fraser, V. J., & Kollef, M. H. (2004) · Chest · doi:10.1378/chest.125.5.1791 · Cited by 307
Falagas, M. E., Rafailidis, P. I., Ioannidou, E., Alexiou, V. G., Matthaiou, D. K., Karageorgopoulos, D. E., Kapaskelis, A., Nikita, D., & Michalopoulos, A. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.005 · Cited by 300
Defining, treating and preventing hospital acquired pneumonia: European perspective
Torres, A., Ewig, S., Lode, H., Carlet, J., & For The European HAP working group (2009) · Intensive Care Medicine · doi:10.1007/s00134-008-1336-9 · Cited by 298
Michalopoulos, A. S., Tsiodras, S., Rellos, K., Mentzelopoulos, S., & Falagas, M. E. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.01043.x · Cited by 292
Multidrug-Resistant Gram-Negative Infections: What are the Treatment Options?
Giamarellou, H., & Poulakou, G. (2009) · Drugs · doi:10.2165/11315690-000000000-00000 · Cited by 288
A review on colistin nephrotoxicity
Ordooei Javan, A., Shokouhi, S., & Sahraei, Z. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1865-4 · Cited by 287
Rotstein, C., Evans, G., Born, A., Grossman, R., Light, R. B., Magder, S., McTaggart, B., Weiss, K., & Zhanel, G. G. (2008) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2008/593289 · Cited by 282
Renal and neurological side effects of colistin in critically ill patients
Spapen, H., Jacobs, R., Van Gorp, V., Troubleyn, J., & Honoré, P. M. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-14 · Cited by 281
A new strategy to fight antimicrobial resistance: the revival of old antibiotics
Cassir, N., Rolain, J.-M., & Brouqui, P. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00551 · Cited by 280
Markou, N., Apostolakos, H., Koumoudiou, C., Athanasiou, M., Koutsoukou, A., Alamanos, I., & Gregorakos, L. (2003) · Critical Care · doi:10.1186/cc2358 · Cited by 278
Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings
Garnacho-Montero, J., Ortiz-Leyba, C., Fernández-Hinojosa, E., Aldabó-Pallás, T., Cayuela, A., Marquez-Vácaro, J. A., Garcia-Curiel, A., & Jiménez-Jiménez, F. J. (2005) · Intensive Care Medicine · doi:10.1007/s00134-005-2598-0 · Cited by 276
Self-citationArroyo, L. A., Herrera, C. M., Fernandez, L., Hankins, J. V., Trent, M. S., & Hancock, R. E. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00256-11 · Cited by 275
Colistin: new lessons on an old antibiotic
Yahav, D., Farbman, L., Leibovici, L., & Paul, M. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03734.x · Cited by 259
Acinetobacter baumannii: a universal threat to public health?
Giamarellou, H., Antoniadou, A., & Kanellakopoulou, K. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.02.013 · Cited by 258
Metadata
- Authors
- Garnacho‐Montero, J., Ortiz‐Leyba, C., Jimenez‐Jimenez, F. J., Barrero‐Almodovar, A. E., Garcia‐Garmendia, J. L., Bernabeu‐WittelI, M., Gallego‐Lara, S. L., & Madrazo‐Osuna, J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-05
- Volume
- 36
- Issue
- 9
- Pages
- 1111-1118
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2124996394
- Cited by
- 470
- References
- 28
- FWCI
- 15.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.